Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25980626 | 0.80 | MEN1 (0.38) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL15908130 | 0.80 | CYP1A2 (0.39) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL22661649 | 0.78 | GAA (0.36) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL14415917 | 0.77 | KMT2A (0.38) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL14438140 | 0.76 | ALDH1A1 (0.45) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL25588991 | 0.76 | ALDH1A1 (0.37) | ALDH1A1POLBSMN1; SMN2LMNAHTT | |
| SCHEMBL20436763 | 0.76 | ALDH1A1 (0.37) | ALDH1A1POLBSMN1; SMN2LMNAHTT | |
| SCHEMBL15087768 | 0.73 | GAA (0.34) | ALDH1A1POLBSMN1; SMN2LMNAHTT | |
| SCHEMBL20329204 | 0.72 | POLB (0.31) | ALDH1A1POLBSMN1; SMN2LMNAHTT | |
| SCHEMBL17589373 | 0.72 | GAA (0.35) | MEN1KMT2AALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457698-B2 | Chiral reagents for preparation of substituted phosphorodiamidate morpholino oligomers | EISAI R&D MANAGEMENT CO., LTD (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20180222932-A1 | CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457698-B2 | Chiral reagents for preparation of substituted phosphorodiamidate morpholino oligomers | PMM2, MPHOSPH6, PFAS | MEN1 864/4885KMT2A 4189/4885ALDH1A1 4476/4885 |
| US-20180222932-A1 | CHIRAL REAGENTS FOR PREPARATION OF HOMOGENEOUS OLIGOMERS | RNGTT, MPHOSPH6, PMM2 | MEN1 1121/4885KMT2A 3898/4885ALDH1A1 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.